BridgeBio to Host Achondroplasia Investor Webinar on Friday, January 9th at 8:00 am ET

Rhea-AI Summary

BridgeBio (Nasdaq: BBIO) will host an investor webinar on Friday, January 9, 2026 at 8:00 am ET featuring Janet Legare, M.D., investigator in the registrational Phase 3 PROPEL 3 study of infigratinib for children with achondroplasia.

Dr. Legare will overview achondroplasia pathophysiology, current unmet need, and the rationale for evaluating infigratinib. Executive members of the skeletal dysplasia program will review the infigratinib clinical program and the ongoing PROPEL 3 study, with topline results expected in Q1 2026.

The live webcast is available via the company’s Events & Presentations page and a replay will be posted for 30 days.

Key Figures

Webinar date January 9, 2026 Investor webinar on achondroplasia and infigratinib

Webinar time 8:00 am ET Start time for achondroplasia investor webinar

PROPEL 3 phase Phase 3 PROPEL 3 registrational study of infigratinib in children with achondroplasia

Webcast replay duration 30 days Replay available on BridgeBio website after the webinar

Quarter for topline results Q1 2026 Expected timing of PROPEL 3 topline results

Market Reality Check

$78.23 Last Close

Volume Volume 1,198,889 is below the 20-day average of 1,737,310 shares ahead of the webinar. low

Technical Price $76.49 is trading above the 200-day MA of $49.64 and 2.49% below the 52-week high.

Peers on Argus

Peers show mixed but mostly positive moves, with BMRN, IONS, ASND, and SMMT up between 0.42% and 1.91%, while EXEL is down 0.25%. No momentum scanner signals sector-wide action.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 22	Inducement grants	Neutral	-0.9%	Inducement RSU grants totaling 29,472 shares for nine new employees.
Nov 25	Investor conferences	Neutral	-0.5%	Management participation in December investor conference fireside chats.
Nov 19	Inducement grants	Neutral	-1.4%	Inducement equity grants totaling 34,199 RSUs for new employees.
Nov 04	Investor conferences	Neutral	-1.0%	Management presenting at two November 2025 healthcare investor conferences.
Nov 03	Scientific data	Positive	-1.1%	ATTRibute-CM clinical data with mortality and hospitalization reductions for acoramidis.

Pattern Detected

Recent news and conference items have typically seen modest negative next-day moves despite neutral or constructive content.

Recent Company History

Over the last several months, BridgeBio’s news flow has centered on routine corporate items and scientific visibility. Inducement equity grants on Nov 19 and Dec 22, 2025 were followed by small declines of -1.4% and -0.9%. Investor conference participation in early and late Nov 2025 also saw mild pullbacks of roughly -0.5% to -1.0%. A scientific data presentation from the ATTRibute-CM program on Nov 3, 2025 likewise coincided with a -1.05% move, suggesting a pattern of modest post-news softness.

Market Pulse Summary

This announcement schedules an investor webinar to review achondroplasia, infigratinib’s role, and the registrational Phase 3 PROPEL 3 program, with topline results expected in Q1 2026. It reinforces BridgeBio’s focus on skeletal dysplasia and patient need but does not provide new efficacy or safety data. Historically, similar conference and corporate updates have seen limited lasting impact, so investors may watch for the actual PROPEL 3 topline readout and any subsequent regulatory steps as key milestones.

Key Terms

registrational clinical

"investigator in PROPEL 3, the registrational Phase 3 study of infigratinib"

Used as an adjective, 'registrational' describes data, studies, or trials designed specifically to convince health regulators to approve a drug, device, or treatment. Investors care because successful registrational results are the most direct path to market authorization and revenue; think of them as the final exam or blueprint that regulators use to decide whether a product can be sold widely, so passing them can materially change a company’s value.

phase 3 clinical

"investigator in PROPEL 3, the registrational Phase 3 study of infigratinib"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

pathophysiology medical

"overview of achondroplasia, specifically focusing on pathophysiology, the current unmet need"

Pathophysiology is the study of how and why diseases develop and affect the body’s normal functions. It explores the changes that occur in the body’s systems when illness strikes, much like understanding how a malfunction in a machine causes it to break down. Recognizing these processes helps identify potential problems early and develop effective treatments, which can influence how investors assess health-related industries and innovations.

skeletal dysplasia medical

"rationale for evaluating infigratinib as a treatment for skeletal dysplasia, including achondroplasia"

A group of inherited conditions that affect how bones and cartilage grow, often causing unusually short stature, bone deformities or joint problems. For investors, these disorders matter because they create specific markets for treatments, genetic tests and medical devices; successful drugs or diagnostics can win regulatory incentives and long-term patient demand, much like supplying a niche but steady customer base for a specialized product.

clinical development program medical

"team will review the ongoing infigratinib clinical development program and discuss the ongoing Phase 3"

A clinical development program is the organized series of studies and trials that test a potential medicine or medical product in humans to evaluate safety, the right dose, and whether it works, usually moving through early to late stages required for regulatory approval. For investors it matters because the program sets the project’s timeline, costs, and key milestones—like checkpoints on a roadmap—where positive results can sharply increase value and failures or delays can sharply reduce it.

topline results clinical

"ongoing Phase 3 PROPEL 3 study, for which topline results are expected in Q1 2026"

Topline results are the initial, high-level summary of the most important outcomes from an event such as a clinical trial or a company reporting period — for a drug study this means whether the main goals were met and basic safety info, and for a company it often means headline revenue and profit figures. Investors care because these summaries act like a headline that quickly signals whether prospects have improved or worsened, often driving immediate market reactions before the full details are released.

AI-generated analysis. Not financial advice.

PALO ALTO, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced the Company will host an investor webinar on Friday, January 9, 2026 at 8:00 am ET with Janet Legare, M.D., Professor in the Divisions of Genetics and Metabolism and Developmental Pediatrics and Rehabilitation Medicine in the Department of Pediatrics at the University of Wisconsin (UW) School of Medicine and Public Health and investigator in PROPEL 3, the registrational Phase 3 study of infigratinib for children with achondroplasia. Dr. Legare also serves as director of both the Midwest Regional Bone Dysplasia Clinic and the Neuromotor Development Clinic, both affiliated with UW Health Kids.

Dr. Legare will provide an overview of achondroplasia, specifically focusing on pathophysiology, the current unmet need, and the rationale for evaluating infigratinib as a treatment for skeletal dysplasia, including achondroplasia. Dr. Legare actively engages with leading professional organizations, including the American Academy of Pediatrics, the Society for Pediatric Research, the American College of Medical Genetics, Little People of America, and the International Skeletal Dysplasia Society, and holds an affiliate appointment in the Department of Neurological Surgery. Her clinical expertise spans the diagnosis, management, and long-term care of children with skeletal dysplasia.

In addition to Dr. Legare, executive members of the skeletal dysplasia program team will review the ongoing infigratinib clinical development program and discuss the ongoing Phase 3 PROPEL 3 study, for which topline results are expected in Q1 2026.

To access the live webcast of BridgeBio’s investor webinar, please visit the “Events & Presentations” page within the Investors section of the BridgeBio website at http://investor.bridgebio.com. A replay of the webcast will be available on the BridgeBio website for 30 days following the event.

About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn, X, Facebook, Instagram, and YouTube.

BridgeBio Media Contact:
Bubba Murarka, Executive Vice President
contact@bridgebio.com  
(650)-789-8220

BridgeBio Investor Contact:
Chinmay Shukla, Senior Vice President, Strategic Finance
ir@bridgebio.com

FAQ

When is the BridgeBio (BBIO) achondroplasia investor webinar?

The webinar is scheduled for Friday, January 9, 2026 at 8:00 am ET.

Who is presenting at the BridgeBio (BBIO) investor webinar on January 9, 2026?

Janet Legare, M.D., investigator in the Phase 3 PROPEL 3 study, will present alongside executive members of the skeletal dysplasia program team.

What topics will BridgeBio (BBIO) cover in the achondroplasia webinar?

The webinar will cover achondroplasia pathophysiology, current unmet need, the rationale for infigratinib, and updates on the infigratinib clinical development program.

When are topline results for the PROPEL 3 (infigratinib) study expected?

Topline results for the PROPEL 3 study are expected in Q1 2026.

How can investors watch the BridgeBio (BBIO) webinar and replay?

Watch the live webcast on the company’s Events & Presentations page at investor.bridgebio.com; a replay will be available on the website for 30 days after the event.